Expression of MHC I at the cell surface is essential for presenting peptides to circulating cytotoxic T cells. Interference with a number of components of the antigen processing machinery is an immune evasion mechanism that has been highlighted in a number of malignancies. Endoplasmic reticulum aminopeptidase 1 (ERAP1), a key component of the antigen processing pathway, undertakes the final N-terminal processing of peptide epitopes for MHC I presentation. ERAP1 acts to regulate and define the repertoire of peptides at the cell surface; changes in ERAP1 activity have significant consequences on CD8+ T cell and NK cell responses. Single nucleotide polymorphisms (SNPs) in ERAP1 have been strongly associated with a number of autoimmune conditions, viral infections and cancer. The resence of SNPs in ERAP1 significantly alter the ability to generate stable peptide epitopes for presentation, thereby altering the peptidome and subsequent immune response. Interestingly, ERAP1 variants have been significantly associated with prognosis and survival in virally induced cancer. Here we discuss the emerging role of ERAP1 activity in malignancy, and the contribution of ERAP1 SNP variants in the generation or destruction of epitopes in tumour cells. This potential immune evasion strategy employed by a number of tumour cells may therefore predispose individuals to cancer based on their ability to generate the required epitopes and form adequate immune response.
Keywords:
Published on: Sep 21, 2015 Pages: 28-35
Full Text PDF
Full Text HTML
DOI: 10.17352/jvi.000007
CrossMark
Publons
Harvard Library HOLLIS
Search IT
Semantic Scholar
Get Citation
Base Search
Scilit
OAI-PMH
ResearchGate
Academic Microsoft
GrowKudos
Universite de Paris
UW Libraries
SJSU King Library
SJSU King Library
NUS Library
McGill
DET KGL BIBLiOTEK
JCU Discovery
Universidad De Lima
WorldCat
VU on WorldCat
PTZ: We're glad you're here. Please click "create a new query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."